Abstract: The invention relates to an improved extract from Ginkgo biloba leaves, a method of preparation of the same and pharmaceuticals containing the extract.

Abstract: The invention relates to a method of preparation of an improved extract from Ginkgo biloba leaves and to pharmaceuticals containing the extract.

Abstract: To permit easy insertion and removal of a compact fluorescent lamp (2) in and from a socket, the socket is formed with a body (3) having an engagement surface wall (5) from which a shelf (4) projects bounded by side walls (22, 23) to define a base reception cavity (25). The engagement wall (5) is formed with slits (11) to permit terminal pins (13) from the lamp to pass therethrough, for engagement with electrical terminal contacts (T). The lamp is held in position by a resilient catch or latch or snap-over element (14) movably mounted on the engagement wall (5), for example by being molded on a separated strip portion (15) forming a resilient holder, and projecting from the engagement wall (5), to snap over the end portion of a base (35) of the lamp, when inserted. To release the lamp, the catch can be bent backwardly. Holding projections (30) on the shelf lock the lamp in position.

Abstract: Dry extract from kava-kava drug having a total content of kava lactones of at least 50% by weight and a flavokawin content of at the most 0.3% by weight. The extract is distinguished by good water solubility and high bioavailability after oral administration. To increase the kava lactone content in the extract and decrease the flavokawin content, a process is proposed in which the raw extract is brought into solution and the content of flavokawins diminished by cold precipitation or by solvent distribution, whereafter the solution is concentrated to dryness. Drugs are made using the dry extract.

Abstract: Novel esters of amino acids are proposed of which the alcoholic components are formed from threo-4-alkoxy-5-arylhydroxymethyl-2(5H)-furanones. These esters may be present in the form of racemates, pure diastereomers or enantiomers or in the form of diastereomer or enantiomer mixtures. The compounds are anticonvulsive and antiepileptic and due to their good water solubility are easier to administer and more readily absorbable than known anti-convulsives and antiepileptics. A novel process is also disclosed which leads stereoselectively to the diastereomers or the enantiomers or mixtures thereof. The invention further relates to the use of the novel amino acid esters as pharmaceutical preparations and in the production of pharmaceutical preparations.

Abstract: A vibrator conveyor system, for example in the form of a circular or linear conveyor, has a reciprocating plate adapted for carrying a container, and electromagnetic oscillating armature motors for moving said plate along a primary advancement direction or vector; each motor has a stationary stator, an armature secured to the reciprocating plate, and an excitation coil driven by alternating current or pulsating direct current, the coil being disposed on a pole piece the stator, the pile piece having a stator pole surface cooperating with an armature pole surface. The reciprocating plate is elastically supported by spring elements in a manner limiting its vertical and horizontal motion. The elongated spring elements are aligned along at least a portion of the rim of the plate with equal inclination with respect to a plane containing the conveyor advancement vector, and are fastened to the plate.

Abstract: Medicaments containing bilobalide which can be used to control nervous diseases are described.

Abstract: The present invention provides 5-arylalkyl-4-alkoxy-2(5H)-furanones of the formula: ##STR1## wherein the oxygen atoms on C-5 and C-.alpha., relative to one another, are in the threo-position, with the exclusion of those compounds of the formula (I) wherein R.sup.2 is H or CH.sub.3 when n=0 or 2, R.sup.o =H, R.sup.1 =CH.sub.3, R.sup.3 =H and R.sup.4 =H.The present invention also provides processes for their preparation, as well as new 3-alkoxy-5-(subst.)-phenyl-2(E), 4(E)-pentadienoates as reactive intermediates for the preparation of the new furanone derivatives.The new furanone derivatives of the threo series are active as anticonvulsives/anti-epileptics. Therefore, the present invention also provides medicaments which contain these new furanone derivatives, as well as known furanones, the anticonvulsive/anti-epileptic effectiveness of which has been found for the first time.

Abstract: In a method for making U-shaped core laminations and T-shaped magnetic circuit closing elements fitting in between the legs thereof, in a choke, ballast or transformer, in particular for use as an accessory element in gas discharge lamps, two mutually offset rows of U-shaped core laminations having their open ends facing one another and having the pairs of adjacent outer legs thereof interfitting with one another are punched out in such a manner that one pair of outer legs of one row is laterally adjacent to one pair of outer legs of the other row, and the T-shaped magnetic circuit closing elements, with cross legs adjacent to the connecting middle legs of the U-shaped core lamination are punched out of the free spaces located between the ends of the pairs of outer legs and the connecting legs, located facing tem and spaced apart from them, of the U-shaped core laminations.

Abstract: 1.4;3.6-Dianhydrohexitol nitrates substituted by purine bases, namely, adenyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ia as well as theophyllinyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ib, ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and, independently of one another signify(a) a hydrogen atom,(b) a straight-chained or branched alkyl group with 1 to 7 C-atoms,(c) an .omega.-phenylalkyl group, whereby the alkyl group has 1 to 7 C-atoms and whereby the phenyl ring can be halogen-substituted in the p-position, or wherein(d) R.sup.1 signifies one of the residues given under (a) to (c) and R.sup.2 an acyl radical or an aliphatic, possibly methyl-substituted monocarboxylic acid with 2 to 7 C-atoms, or wherein(e) R.sup.1 and R.sup.

Abstract: Medicaments containing bilobalid which can be used to control nervous diseases are described.

Abstract: Alkylaminodesoxy-1.4;3.6-dianhydrohexitol nitrates substituted by purine bases of the general formula I, ##STR1## wherein R.sup.1 signifies a hydrogen atom or a lower alkyl group with 1 to 4 C-atoms, X a straight-chained or branched alkyl or hydroxyalkyl group with 1 to 7 C-atoms, Y a 1,3-dialkylxanthin-7-yl or a 3,7-dialkylxanthin-1-yl group, each with straight or branched-chained alkyl groups with 1 to 5 C-atoms, or an adenin-9-yl group, as well as their physiologically acceptable acid-addition salts. Process for the preparation of said compounds and pharmaceutical compositions containing said compounds.

Abstract: Aminodesoxy-1.4;3.6-dianhydrohexitol derivatives of the general formula I, ##STR1## wherein R.sup.1 and R.sup.2 in each case independently of one another, signifies a hydrogen atom or a lower alkyl group with 1 to 4 C-atoms or wherein R.sup.1 signifies a hydrogen atom and R.sup.2 an adamant(1)yl radical or wherein R.sup.1 , and R.sup.2, together with the nitrogen atom to which they are attached, (a) signify the residue of a cyclic, non-aromatic secondary amine possibly containing a further hetero atom or (b) the aden(9)yl radical possibly mono- or disubstituted on the 6-amino group or (c) the 6-alkylmercaptopurin(9)yl radical or (d) the theophyllin-(7)yl radical or (e) the 6-chloropurin-9-yl radical or wherein R.sup.1 signifies a hydrogen atom or a lower alkyl group with 1 to 4 C-atoms and R.sup.2 an .omega.-theophyllin(7)ylalkyl radical or an .omega.-theobromin-1-ylalkyl radical or an .omega.

Abstract: The present invention provides corynantheine derivatives of the general formula: ##STR1## wherein R is a hydrogen or alkali metal atom, an ammonium group or the residue of an amine or an alkyl radical containing up to 4 carbon atoms; and the physiologically acceptable acid-addition salts thereof.The present invention also provides processes for the preparation of these corynantheine derivatives and pharmaceutical compositions containing them. Furthermore, the present invention is concerned with the use of dihydrocorynantheine as an antihypertonic.

Abstract: 1.4;3.6-Dianhydrohexitol nitrates substituted by purine bases, namely, adenyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ia as well as theophyllinyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ib, ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and, independently of one another signify(a) a hydrogen atom,(b) a straight-chained or branched alkyl group with 1 to 7 C-atoms,(c) an .omega.-phenylalkyl group, whereby the alkyl group has 1 to 7 C-atoms and whereby the phenyl ring can be halogen-substituted in the p-position, or wherein(d) R.sup.1 signifies one of the residues given under (a) to (c) and R.sup.2 an acyl radical or an aliphatic, possibly methyl-substituted monocarboxylic acid with 2 to 7 C-atoms, or wherein(e) R.sup.1 and R.sup.

Abstract: Aminodesoxy-1.4;3.6-dianhydrohexitol derivatives of the general formula I, ##STR1## wherein R.sup.1 and R.sup.2, in each case independently of one another, signifies a hydrogen atom or a lower alkyl group with 1 to 4 C-atoms or wherein R.sup.1 signifies a hydrogen atom and R.sup.2 an adamant(1)yl radical or wherein R.sup.1 and R.sup.2, together with the nitrogen atom to which they are attached, (a) signify the residue of a cyclic, non-aromatic secondary amine possibly containing a further hetero atom or (b) the aden(9)yl radical possibly mono- or disubstituted on the 6-amino group or (c) the 6-alkylmercaptopurin(9)yl radical or (d) the theophyllin(7)yl radical or (e) the 6-chloropurin-9-yl radical or wherein R.sup.1 signifies a hydrogen atom or a lower alkyl group with 1 to 4 C-atoms and R.sup.2 an .omega.-theophyllin(7)ylalkyl radical or an .omega.-theobromin-1-ylalkyl radical or an .omega.

Abstract: Reactive iridoid derivates represented by the following general formula ##STR1## (wherein R represents a hydrogen atom, an alkyl group with 1 to 5 carbon atoms, an acyl group with 2 to 6 C atoms, an unsubstituted aralkyl group with 7 to 12 C atoms, a methanesulfonyl- or toluenesulfonyl group, a benzoyl-, a preferably para-substituted nitrobenzoyl- or chlorobenzoyl group, or a tetrahydropyranyl group), process for the manufacture of said derivatives starting from catapol as an easily obtainable natural substance and use of said derivatives as intermediates for the manufacture of prostanoids.